We read the research so you don’t have to.
As a Dermatology podcast, we do things a little differently: we start every episode with immediately actionable clinical pearls—right up front. No fluff, no waiting.
So even if you’ve got five minutes between patients, you’ll still walk away with something you can actually use in clinic that day.
And if you want more—the “why,” the nuance, the deeper dive into the data—just keep listening.
Think of it as dermatology on your terms: quick when you need it, more when you want it.
We’re not here to just read papers and repeat the results.
We’re here to take the data, the ideas, the nuance—and make them more approachable, more usable…and ultimately more relevant to what actually happens in clinic.
Publisher
Diego Ruiz Dasilva, MD, FAAD & Graham Litchman, DO, MS, FAAD
Host Graham Litchman, DO, MS, interviews experts on the gut-skin connection, separating science from hype regarding diet and probiotics for eczema.
12 Oct 2026TRANSCRIPT
New Data, Who Dis? Fall Clinical 2026 pt 1
Host Graham Litchman and Diego unpack practice-changing insights and emerging therapies from Fall Clinical 2026, separating hype from what truly matters in dermatology.
5 Oct 2026
Isotretinoin Labs, Lymphoma & Losing Sight: What’s the Real Risk?
Host Graham Litchman, DO, MS, and industry experts discuss the real risks of isotretinoin and Dupixent, helping clinicians discern true safety signals from mere association.
28 Sept 2026TRANSCRIPT
Beyond the Blade: Skin Cancer Without Surgery & Live Vaccines on Dupixent
Host Graham Litchman, DO, MS, explores nonsurgical skin cancer treatments and the evolving advice on live vaccines for Dupixent patients.
21 Sept 2026TRANSCRIPT
From Bald to Bold - and Dry to Wet
Graham Litchman, DO, MS and Diego Ruiz Dasilva, MD discuss upadacitinib for alopecia areata and wound care after dermatologic surgery, offering clinicians high-yield insights.
8 Sept 2026TRANSCRIPT
Dermatitis Flares & IL-31: Real or Imagined?
Host Dr. [Host Name] interviews Dr. [Guest Name], a leading dermatologist, exploring whether IL-31 blockade effectively prevents dermatitis flares in atopic dermatitis treatment.
31 Aug 2026
Wheal Talk: Comparing CSU Treatments
With new therapies rapidly expanding the CSU treatment landscape, which options actually come out on top? We unpack a recent meta-analysis comparing efficacy across treatments and discuss what the rankings mean for real-world treatment decisions. Skin in the Game delivers high-yield dermatology quick hits for busy clinicians. Hosted by: • Graham Litchman, DO, MS — Vivida Dermatology, Las Vegas, NV • Diego Ruiz Dasilva, MD — Forefront Dermatology, Virginia Beach, VA We read the...
24 Aug 2026
The Biosimilar Paradox: Cheaper Drug, Bigger Bill
Biosimilars promise lower drug costs - but are patients actually saving? We unpack the surprising reality that despite lower prices, biosimilars can leave patients with higher out-of-pocket costs and discuss what this means for access and affordability in dermatology. Skin in the Game delivers high-yield dermatology quick hits for busy clinicians. Hosted by: • Graham Litchman, DO, MS — Vivida Dermatology, Las Vegas, NV • Diego Ruiz Dasilva, MD — Forefront Dermatology, Virginia B...
17 Aug 2026
Beyond Morning Stiffness: Seeing the Damage in PsA with Dr. David Oberlin
Radiographic progression in psoriatic arthritis isn’t always as straightforward as the headline results suggest. We discuss David Oberlin’s recent JAAD paper examining IL-23 inhibitor trials, why trial design matters when interpreting structural outcomes, and what dermatologists should understand when treating patients with PsA. Skin in the Game delivers high-yield dermatology quick hits for busy clinicians. Hosted by: • Graham Litchman, DO, MS — Vivida Dermatology, Las Vegas, NV &nbs...
10 Aug 2026
To Cut or Not to Cut? The Dysplastic Nevus Discussion
Few topics in dermatology generate more debate than the management of dysplastic nevi. Should every positive margin be re-excised? Does the degree of atypia matter? And what does the evidence actually tell us about melanoma risk? In this episode of Skin in the Game, Drs. Diego Ruiz Dasilva and Graham Litchman dive into one of the most common—and controversial—decisions in everyday dermatology. They separate long-held dogma from current evidence and share a practical, patient-centered approach...
3 Aug 2026
From Black Box to Bargain Price: The Tofacitinib Comeback?
Tofacitinib was the first oral JAK inhibitor to transform the treatment of inflammatory disease but after the ORAL Surveillance trial, its boxed warning reshaped how many clinicians viewed the entire class. Now, everything is changing again. With generic tofacitinib becoming dramatically less expensive, clinicians are asking whether it’s time to take another look. In this episode of Skin in the Game, Drs. Diego Ruiz Dasilva and Graham Litchman unpack the history of tofacitinib, what the boxed...
27 Jul 2026TRANSCRIPT
Which Psoriasis Therapy Comes Out on Top? Breaking Down the Latest Network Meta-Analysis
With more treatment options than ever, choosing the right therapy for psoriasis isn’t always straightforward. In this episode of Skin in the Game, we break down the latest JAMA Dermatology meta-analysis comparing systemic treatments for plaque psoriasis. We discuss which therapies rise to the top, the strengths and limitations of network meta-analyses, and what these findings mean for real-world clinical practice. Join us for a practical, evidence-based discussion with actionable takeaways fo...
20 Jul 2026
The IDENTITY Trial - Can Precision Medicine Transform Atopic Dermatitis Care?
For decades, systemic therapy selection in atopic dermatitis has largely relied on clinical judgment and trial-and-error. The prospective IDENTITY study by Silverberg and colleagues challenges that paradigm. In this episode of Skin in the Game, we unpack the landmark JAAD study evaluating a 487-gene expression profile designed to identify the dominant inflammatory pathway in individual patients and guide systemic treatment selection. We discuss how the test works, review the study design and ...
13 Jul 2026
Finasteride, Dutasteride & Sexual Side Effects - What Does the Evidence Really Show?
Few topics in dermatology spark more debate than the sexual side effects of oral finasteride. In this episode of Skin in the Game, we break down the latest evidence comparing finasteride and dutasteride, including a new pharmacovigilance analysis, and discuss what these data can—and can’t—tell us about real-world risk. We explore the strengths and limitations of adverse event databases, the role of reporting bias and the nocebo effect, and how to counsel patients using the best available evid...
6 Jul 2026TRANSCRIPT
Getting Some Skin in the Game
Welcome to Skin in the Game, a dermatology podcast delivering high-yield clinical pearls for busy clinicians. Hosted by dermatologists Graham Litchman and Diego Ruiz Dasilva: we break down the latest research and translate it into practical insights you can use immediately in clinic. In our inaugural episode, we explain the philosophy behind the podcast and discuss the paper “Assessing Risk Amid Uncertainty Inside and Outside the Dermatology Clinic” by Vanderweil et al. Together, we explore h...
Inside a recent episode
Gut Check: Probiotics, Diet, and the Eczema Hype
Published 19 Oct 2026 · Transcript excerpt
[…] This is about Senebrea, de la Torre, and colleagues, and this was published in Dermatitis in 2025. So researchers studied about 124 patients with atopic dermatitis, assessing the Mediterranean diet adherence, physical activity, and then of course, eczema severity and itch. And you know what? The people whose eating patterns were more closely followed by the Mediterranean diet actually had less severe disease. So greater consumption of vegetables, fruits, legumes, and fish was associated with lower severity. And lower diet adherence was also associated with more itch. Physical activity showed favorable associations as well. […]
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
